To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Comparison of risedronate, alendronate, zoledronate, and ibandronate in those with low BMD

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
September 2016

Comparison of risedronate, alendronate, zoledronate, and ibandronate in those with low BMD

Vol: 5| Issue: 9| Number:39| ISSN#: 2564-2537
Study Type:Meta analysis
OE Level Evidence:2
Journal Level of Evidence:N/A

Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis

Bone. 2016 Aug;89:52-8

Contributing Authors:
J Sanderson M Martyn-St James J Stevens E Goka R Wong F Campbell P Selby N Gittoes S Davis

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

A total of 27 randomized controlled trials were included in this network meta-analysis investigating the comparative efficacies of bisphosphonates - including alendronate, ibandronate, risedronate, and zoledronic acid - versus placebo or control in patients with low bone mineral density. All studied drugs demonstrated significant effects on vertebral fracture incidence and bone mineral density of ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.